Retigabine, a drug that opens voltage-gated potassium channels, has been shown to abolish stress-induced cognitive defects; normalize the expression of PGC-1α, β-catenin, and USP2; and alleviate the increase in phosphorylated mammalian target of rapamycin (mTOR) and autophagy components [120]. The gene discussed is MTOR; the disease is Cognitive impairment.